Small Molecules CDMO (Small Molecule Contract Development and Manufacturing Organization) refers to a company that specializes in providing development and production services for small molecule drugs to pharmaceutical and biotech companies. Small molecule drugs generally refer to compounds with a smaller molecular weight, which are usually used to treat various diseases. CDMO provides a comprehensive service, including external third-party programs and their knowledge and development. As pharmacological substances become more and more complex, pharmaceutical companies face many problems in researching and manufacturing drug substances. More rapid research and production are needed to bring ideas to market faster, and many pharmaceutical companies prioritize cost control or cost reduction.
The global Small Molecules CDMO Services market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Small Molecules CDMO Services is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Small Molecules CDMO Services is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Small Molecules CDMO Services in SME Pharmaceutical Company is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Small Molecules CDMO Services include Novartis, Thermo Fisher Scientific Inc, Pfizer, Lonza, Evonik, WuXi AppTec, Cambrex, Charles River Laboratories, Almac, Ajinomoto Bio, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Small Molecules CDMO Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Small Molecules CDMO Services.
The Small Molecules CDMO Services market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Small Molecules CDMO Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Small Molecules CDMO Services companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Thermo Fisher Scientific Inc
Pfizer
Lonza
Evonik
WuXi AppTec
Cambrex
Charles River Laboratories
Almac
Ajinomoto Bio
Porton
CordenPharma
Eurofins Scientific
3xper Innoventure
Euroapi
Aragen
OncoBone Ltd
Aurigene Pharmaceutical Services Ltd
Onyx Scientific Limited
Segment by Type
Oral Medications
Injectable Medications
Topical Medications
Segment by Application
SME Pharmaceutical Company
Large Pharmaceutical Company
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Small Molecules CDMO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Small Molecules CDMO Services Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral Medications
1.2.3 Injectable Medications
1.2.4 Topical Medications
1.3 Market by Application
1.3.1 Global Small Molecules CDMO Services Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 SME Pharmaceutical Company
1.3.3 Large Pharmaceutical Company
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Small Molecules CDMO Services Market Perspective (2019-2030)
2.2 Global Small Molecules CDMO Services Growth Trends by Region
2.2.1 Global Small Molecules CDMO Services Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Small Molecules CDMO Services Historic Market Size by Region (2019-2024)
2.2.3 Small Molecules CDMO Services Forecasted Market Size by Region (2025-2030)
2.3 Small Molecules CDMO Services Market Dynamics
2.3.1 Small Molecules CDMO Services Industry Trends
2.3.2 Small Molecules CDMO Services Market Drivers
2.3.3 Small Molecules CDMO Services Market Challenges
2.3.4 Small Molecules CDMO Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Small Molecules CDMO Services Players by Revenue
3.1.1 Global Top Small Molecules CDMO Services Players by Revenue (2019-2024)
3.1.2 Global Small Molecules CDMO Services Revenue Market Share by Players (2019-2024)
3.2 Global Small Molecules CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Small Molecules CDMO Services Revenue
3.4 Global Small Molecules CDMO Services Market Concentration Ratio
3.4.1 Global Small Molecules CDMO Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Small Molecules CDMO Services Revenue in 2023
3.5 Global Key Players of Small Molecules CDMO Services Head office and Area Served
3.6 Global Key Players of Small Molecules CDMO Services, Product and Application
3.7 Global Key Players of Small Molecules CDMO Services, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Small Molecules CDMO Services Breakdown Data by Type
4.1 Global Small Molecules CDMO Services Historic Market Size by Type (2019-2024)
4.2 Global Small Molecules CDMO Services Forecasted Market Size by Type (2025-2030)
5 Small Molecules CDMO Services Breakdown Data by Application
5.1 Global Small Molecules CDMO Services Historic Market Size by Application (2019-2024)
5.2 Global Small Molecules CDMO Services Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Small Molecules CDMO Services Market Size (2019-2030)
6.2 North America Small Molecules CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Small Molecules CDMO Services Market Size by Country (2019-2024)
6.4 North America Small Molecules CDMO Services Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Small Molecules CDMO Services Market Size (2019-2030)
7.2 Europe Small Molecules CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Small Molecules CDMO Services Market Size by Country (2019-2024)
7.4 Europe Small Molecules CDMO Services Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Small Molecules CDMO Services Market Size (2019-2030)
8.2 Asia-Pacific Small Molecules CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Small Molecules CDMO Services Market Size by Region (2019-2024)
8.4 Asia-Pacific Small Molecules CDMO Services Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Small Molecules CDMO Services Market Size (2019-2030)
9.2 Latin America Small Molecules CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Small Molecules CDMO Services Market Size by Country (2019-2024)
9.4 Latin America Small Molecules CDMO Services Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Small Molecules CDMO Services Market Size (2019-2030)
10.2 Middle East & Africa Small Molecules CDMO Services Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Small Molecules CDMO Services Market Size by Country (2019-2024)
10.4 Middle East & Africa Small Molecules CDMO Services Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Small Molecules CDMO Services Introduction
11.1.4 Novartis Revenue in Small Molecules CDMO Services Business (2019-2024)
11.1.5 Novartis Recent Development
11.2 Thermo Fisher Scientific Inc
11.2.1 Thermo Fisher Scientific Inc Company Details
11.2.2 Thermo Fisher Scientific Inc Business Overview
11.2.3 Thermo Fisher Scientific Inc Small Molecules CDMO Services Introduction
11.2.4 Thermo Fisher Scientific Inc Revenue in Small Molecules CDMO Services Business (2019-2024)
11.2.5 Thermo Fisher Scientific Inc Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Small Molecules CDMO Services Introduction
11.3.4 Pfizer Revenue in Small Molecules CDMO Services Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Lonza
11.4.1 Lonza Company Details
11.4.2 Lonza Business Overview
11.4.3 Lonza Small Molecules CDMO Services Introduction
11.4.4 Lonza Revenue in Small Molecules CDMO Services Business (2019-2024)
11.4.5 Lonza Recent Development
11.5 Evonik
11.5.1 Evonik Company Details
11.5.2 Evonik Business Overview
11.5.3 Evonik Small Molecules CDMO Services Introduction
11.5.4 Evonik Revenue in Small Molecules CDMO Services Business (2019-2024)
11.5.5 Evonik Recent Development
11.6 WuXi AppTec
11.6.1 WuXi AppTec Company Details
11.6.2 WuXi AppTec Business Overview
11.6.3 WuXi AppTec Small Molecules CDMO Services Introduction
11.6.4 WuXi AppTec Revenue in Small Molecules CDMO Services Business (2019-2024)
11.6.5 WuXi AppTec Recent Development
11.7 Cambrex
11.7.1 Cambrex Company Details
11.7.2 Cambrex Business Overview
11.7.3 Cambrex Small Molecules CDMO Services Introduction
11.7.4 Cambrex Revenue in Small Molecules CDMO Services Business (2019-2024)
11.7.5 Cambrex Recent Development
11.8 Charles River Laboratories
11.8.1 Charles River Laboratories Company Details
11.8.2 Charles River Laboratories Business Overview
11.8.3 Charles River Laboratories Small Molecules CDMO Services Introduction
11.8.4 Charles River Laboratories Revenue in Small Molecules CDMO Services Business (2019-2024)
11.8.5 Charles River Laboratories Recent Development
11.9 Almac
11.9.1 Almac Company Details
11.9.2 Almac Business Overview
11.9.3 Almac Small Molecules CDMO Services Introduction
11.9.4 Almac Revenue in Small Molecules CDMO Services Business (2019-2024)
11.9.5 Almac Recent Development
11.10 Ajinomoto Bio
11.10.1 Ajinomoto Bio Company Details
11.10.2 Ajinomoto Bio Business Overview
11.10.3 Ajinomoto Bio Small Molecules CDMO Services Introduction
11.10.4 Ajinomoto Bio Revenue in Small Molecules CDMO Services Business (2019-2024)
11.10.5 Ajinomoto Bio Recent Development
11.11 Porton
11.11.1 Porton Company Details
11.11.2 Porton Business Overview
11.11.3 Porton Small Molecules CDMO Services Introduction
11.11.4 Porton Revenue in Small Molecules CDMO Services Business (2019-2024)
11.11.5 Porton Recent Development
11.12 CordenPharma
11.12.1 CordenPharma Company Details
11.12.2 CordenPharma Business Overview
11.12.3 CordenPharma Small Molecules CDMO Services Introduction
11.12.4 CordenPharma Revenue in Small Molecules CDMO Services Business (2019-2024)
11.12.5 CordenPharma Recent Development
11.13 Eurofins Scientific
11.13.1 Eurofins Scientific Company Details
11.13.2 Eurofins Scientific Business Overview
11.13.3 Eurofins Scientific Small Molecules CDMO Services Introduction
11.13.4 Eurofins Scientific Revenue in Small Molecules CDMO Services Business (2019-2024)
11.13.5 Eurofins Scientific Recent Development
11.14 3xper Innoventure
11.14.1 3xper Innoventure Company Details
11.14.2 3xper Innoventure Business Overview
11.14.3 3xper Innoventure Small Molecules CDMO Services Introduction
11.14.4 3xper Innoventure Revenue in Small Molecules CDMO Services Business (2019-2024)
11.14.5 3xper Innoventure Recent Development
11.15 Euroapi
11.15.1 Euroapi Company Details
11.15.2 Euroapi Business Overview
11.15.3 Euroapi Small Molecules CDMO Services Introduction
11.15.4 Euroapi Revenue in Small Molecules CDMO Services Business (2019-2024)
11.15.5 Euroapi Recent Development
11.16 Aragen
11.16.1 Aragen Company Details
11.16.2 Aragen Business Overview
11.16.3 Aragen Small Molecules CDMO Services Introduction
11.16.4 Aragen Revenue in Small Molecules CDMO Services Business (2019-2024)
11.16.5 Aragen Recent Development
11.17 OncoBone Ltd
11.17.1 OncoBone Ltd Company Details
11.17.2 OncoBone Ltd Business Overview
11.17.3 OncoBone Ltd Small Molecules CDMO Services Introduction
11.17.4 OncoBone Ltd Revenue in Small Molecules CDMO Services Business (2019-2024)
11.17.5 OncoBone Ltd Recent Development
11.18 Aurigene Pharmaceutical Services Ltd
11.18.1 Aurigene Pharmaceutical Services Ltd Company Details
11.18.2 Aurigene Pharmaceutical Services Ltd Business Overview
11.18.3 Aurigene Pharmaceutical Services Ltd Small Molecules CDMO Services Introduction
11.18.4 Aurigene Pharmaceutical Services Ltd Revenue in Small Molecules CDMO Services Business (2019-2024)
11.18.5 Aurigene Pharmaceutical Services Ltd Recent Development
11.19 Onyx Scientific Limited
11.19.1 Onyx Scientific Limited Company Details
11.19.2 Onyx Scientific Limited Business Overview
11.19.3 Onyx Scientific Limited Small Molecules CDMO Services Introduction
11.19.4 Onyx Scientific Limited Revenue in Small Molecules CDMO Services Business (2019-2024)
11.19.5 Onyx Scientific Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Novartis
Thermo Fisher Scientific Inc
Pfizer
Lonza
Evonik
WuXi AppTec
Cambrex
Charles River Laboratories
Almac
Ajinomoto Bio
Porton
CordenPharma
Eurofins Scientific
3xper Innoventure
Euroapi
Aragen
OncoBone Ltd
Aurigene Pharmaceutical Services Ltd
Onyx Scientific Limited
听
听
*If Applicable.
